Apologies for long delay Enviro. I'm hiding here. Thinking of picking up more.
Hanuman turned me on last year to a promising Alzheimer drug. We both left Casava sumthing too early. After rise from $2 to $10 then some rides around that, I pulled out moved it here:? Ahhhh. It's fluttering around $55 now.
I also did about the same with a direct competitor to us named after the healing Angel, Rafael.
They had some big buy-ins just a couple of years ago. Big backing from the Govt of Israel where they have triLs going on.
Both of us focus on screwing up cancer cell metabolism. Rafael attacks at the cell's site for glucose processing. We attack a little before that. Tyrosineis up in the MANGEMENT area of metabolism.
Both of us are in PANCAN's PRECISION Promise trials. Plenty of room for both of us.
I think we're looking good for the future, primarily in TYME-19 (COVID).
Shared this several times here. In speaking with Investor Relations, updates are going to occur through SEC filings.
Annual report now due any time (10Q)
Our collaboration for TYME-19 is Massachusettes General, Harvard Medical School. Supposed to have a formal presentation on their COVID effort at May 18 Graduation ceremony.
In cancers, we have a collaboration with Eagle Pharmaceutical. Their early March 10Q filing available on Seeking Alpha details out the contract and concerns.
Back to TYME, S8 registration for insider buys detail our business history.
IR says we will be expanding to other cancers. Pancreatic is a BEAR.
Looking myself at Harvard Graduation for NEXT NEWS.
All I got. Eagle Parma indicating we have some time till cancer trials will be reported on. So we go on
Peace
